Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 60 mg - capsule, modified release - excipient ingredients: iron oxide red; sodium lauryl sulfate; indigo carmine; magnesium stearate; titanium dioxide; purified talc; macrogol 6000; iron oxide yellow; gelatin; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; iron oxide black; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 90 mg - capsule, modified release - excipient ingredients: purified talc; iron oxide red; titanium dioxide; magnesium stearate; sodium lauryl sulfate; iron oxide black; macrogol 6000; erythrosine; hydrogenated vegetable oil; gelatin; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

mundipharma pty ltd - morphine sulfate pentahydrate, quantity: 120 mg - capsule, modified release - excipient ingredients: iron oxide yellow; sodium lauryl sulfate; purified talc; titanium dioxide; magnesium stearate; gelatin; indigo carmine; iron oxide black; macrogol 6000; hydrogenated vegetable oil; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; industrial methylated spirit; shellac; sulfuric acid; ammonia - ms mono capsules are indicated for the management of severe pain where: ? other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain, and ? the pain is opioid-responsive, and ? requires daily, continuous, long-term treatment. ms mono capsules are not indicated for use in chronic non-cancer pain other than in exceptional circumstances. ms mono capsules are not indicated as an as-needed (prn) analgesia.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - anagrelide hydrochloride, quantity: 0.61 mg (equivalent: anagrelide, qty 0.5 mg) - capsule, hard - excipient ingredients: lactose; povidone; crospovidone; microcrystalline cellulose; lactose monohydrate; titanium dioxide; gelatin; magnesium stearate - anagrelide apotex capsules are indicated for the treatment of essential thrombocythaemia.

Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - aprepitant (in 125 mg capsule); aprepitant (in 80 mg capsule) - capsule - 125 mg - aprepitant (in 125 mg capsule) 125 mg; aprepitant (in 80 mg capsule) 80 mg

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - piroxicam, quantity: 10 mg - capsule, hard - excipient ingredients: lactose monohydrate; sodium lauryl sulfate; maize starch; magnesium stearate - feldene is indicated for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and ankylosing spondylitis.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 10 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; indigo carmine; purified water; sorbitan monolaurate; erythrosine; gelatin; iron oxide black; sodium lauryl sulfate; propylene glycol; brilliant blue fcf; butan-1-ol; quinoline yellow; allura red ac; sd alcohol 45; sd alcohol 3-a - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; brilliant blue fcf; indigo carmine; butan-1-ol; quinoline yellow; allura red ac; iron oxide black; sd alcohol 45; sd alcohol 3-a; titanium dioxide; purified water; sorbitan monolaurate; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 2.5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; propylene glycol; brilliant blue fcf; indigo carmine; butan-1-ol; quinoline yellow; allura red ac; iron oxide black; sd alcohol 45; sd alcohol 3-a; titanium dioxide; purified water; iron oxide yellow; sorbitan monolaurate; erythrosine; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ramipril, quantity: 1.25 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; titanium dioxide; purified water; iron oxide yellow; sorbitan monolaurate; gelatin; sodium lauryl sulfate; propylene glycol; brilliant blue fcf; indigo carmine; butan-1-ol; quinoline yellow; allura red ac; iron oxide black; sd alcohol 45; sd alcohol 3-a - treatment of hypertension. data are currently not available to support the use of tryzan caps in renovascular hypertension. post myocardial infarction heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160 mmhg or diastolic blood pressure >90 mmhg (or on antihypertensive treatment); total cholesterol >5.2 mmol/l; hdl cholesterol <0.9 mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease